Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? Submitted by Thomas Hughes. First Published: 1/24/2026. 
Quick Look - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback makes the stock look attractively valued. The decline—driven more by market angst than by any clear fundamental weaknesses—appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. The buy zone lines up with trading activity from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates At worst, Abbott's Q4 results and guidance included a few metrics that missed expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings grew at an accelerated pace. Revenue growth missed by several hundred basis points, but margin strength helped offset that shortfall. Adjusted earnings per share (EPS) rose about 12%, coming in slightly above consensus. By segment, the results highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition declined nearly 9%—but those weaknesses were offset by solid gains in Established Pharmaceuticals and MedTech. Established Pharmaceuticals expanded roughly 9%, driven by generics and growth in emerging markets, while MedTech grew about 12.3%, with broad-based strength across sub-segments. Margin expansion was a positive, though some margin metrics still lagged analyst forecasts. Product-mix shifts, strength in MedTech, reduced COVID-19 sales and operational improvements combined to push margins higher overall. Looking ahead, management expects earnings to grow another ~10% in 2026, outpacing revenue and supporting the company's capital-return plans. Capital returns remain central to the investment case. Abbott is a Dividend King, having raised its payout for more than 50 consecutive years, and after the pullback the stock yields roughly 2.5%. The company currently pays out less than half of consensus EPS, leaving room for continued share buybacks—an important offset to dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but no major rating or target changes were issued the morning of the release. The prevailing view is that this remains a fundamentally healthy company that can continue returning capital while reinvesting for growth. The MarketBeat consensus share price target implies meaningful upside—potentially as much as 30%—which could put the stock back near or above prior highs; even the low-end targets imply some upside. Key catalysts include the expanding MedTech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The planned acquisition of Exact Sciences, for example, would broaden Abbott's revenue and profit streams and strengthen its pipeline. The recent price decline has been sharp and, while it could deepen, institutions that accumulated through 2025 are likely buyers on weakness. Early technical support appears in the $105–$110 range, though that level is not yet confirmed. The main risk is that ABT could slip toward the lower end of the buy zone—near $95 or below—before staging a meaningful rebound.
| 
